


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

Claims 1-67. (Canceled)

68. (Previously presented) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;

m is 1;


n is 0;

R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is methyl.

69. (Previously presented) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;

m is 1;

n is 0;


R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is acetyl.

70-71. (Canceled)

72. (New) A pharmaceutical composition comprising a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;

m is 1;

n is 0;


R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is methyl;

and a pharmaceutically acceptable vehicle.

73. (New) A pharmaceutical composition comprising a compound of structural Formula (I):




or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;  
 B is histidine;  
 C is serine;  
 $R^1$  is  $C(O)CH_3$ ;  
 $R^2$  is  $-(CH_2)_mS(O)_nR^5$ ;  
 m is 1;  
 n is 0;  
 $R^3$  is  $-CH_2CONH_2$ ;  
 $R^4$  is  $NH_2$ ;  
 $R^5$  is acetyl;

and a pharmaceutically acceptable vehicle.


74. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;  
 A is proline;  
 B is histidine;  
 C is serine;  
 $R^1$  is  $C(O)CH_3$ ;  
 $R^2$  is  $-(CH_2)_mS(O)_nR^5$ ;  
 m is 1;  
 n is 0;  
 $R^3$  is  $-CH_2CONH_2$ ;  
 $R^4$  is  $NH_2$ ;  
 $R^5$  is methyl.

75. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;

m is 1;

n is 0;


R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;

R<sup>4</sup> is NH<sub>2</sub>;

R<sup>5</sup> is acetyl.

76. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R<sup>1</sup> is C(O)CH<sub>3</sub>;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>m</sub>S(O)<sub>n</sub>R<sup>5</sup>;

m is 1;

n is 0;

R<sup>3</sup> is -CH<sub>2</sub>CONH<sub>2</sub>;


$R^4$  is  $\text{NH}_2$ ;

$R^5$  is methyl; and

b) a pharmaceutically acceptable vehicle.

77. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

$R^1$  is  $\text{C}(\text{O})\text{CH}_3$ ;

$R^2$  is  $-(\text{CH}_2)_m\text{S}(\text{O})_nR^5$ ;

m is 1;

n is 0;

$R^3$  is  $-\text{CH}_2\text{CONH}_2$ ;

$R^4$  is  $\text{NH}_2$ ;

$R^5$  is acetyl; and

b) a pharmaceutically acceptable vehicle.

78. (New) The method of any one of claims 74-77 wherein the patient is a human.